GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Feng Chi Biotech Corp (ROCO:6744) » Definitions » EBIT

Feng Chi Biotech (ROCO:6744) EBIT : NT$24.2 Mil (TTM As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Feng Chi Biotech EBIT?

Feng Chi Biotech's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$13.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$24.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Feng Chi Biotech's annualized ROC % for the quarter that ended in Jun. 2024 was 23.88%. Feng Chi Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 102.47%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Feng Chi Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 27.01%.

Feng Chi Biotech EBIT Historical Data

The historical data trend for Feng Chi Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feng Chi Biotech EBIT Chart

Feng Chi Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 21.71 29.99 28.16 30.48 27.62

Feng Chi Biotech Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.79 12.69 16.82 10.81 13.37

Competitive Comparison of Feng Chi Biotech's EBIT

For the Biotechnology subindustry, Feng Chi Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Feng Chi Biotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Feng Chi Biotech's EV-to-EBIT falls into.


Feng Chi Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$24.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Feng Chi Biotech  (ROCO:6744) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Feng Chi Biotech's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=22.088 * ( 1 - 25.98% )/( (72.775 + 64.135)/ 2 )
=16.3495376/68.455
=23.88 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=301.032 - 27.848 - ( 216.439 - max(0, 54.798 - 255.207+216.439))
=72.775

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=299.852 - 40.658 - ( 218.749 - max(0, 61.359 - 256.418+218.749))
=64.135

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Feng Chi Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=26.74/( ( (27.244 + max(-13.637, 0)) + (24.949 + max(-21.192, 0)) )/ 2 )
=26.74/( ( 27.244 + 24.949 )/ 2 )
=26.74/26.0965
=102.47 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(14.663 + 19.037 + 4.812) - (27.848 + 0 + 24.301)
=-13.637

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(16.011 + 19.67 + 1.801) - (40.658 + 0 + 18.016)
=-21.192

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Feng Chi Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=24.175/89.494
=27.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Feng Chi Biotech EBIT Related Terms

Thank you for viewing the detailed overview of Feng Chi Biotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Feng Chi Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Feng Chi Biotech Corp (ROCO:6744) » Definitions » EBIT
Comparable Companies
ROCO:4197 ROCO:6848 ROCO:6864 ROCO:6662 ROCO:4131 ROCO:3118 ROCO:6917 ROCO:6814 ROCO:6549 ROCO:6808 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
No. 5, Shaoxing North Street, 5th Floor-1, Zhongzheng District, Taipei City, TWN, 100
Website
http://www.fcbiotech.com.tw
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.

Feng Chi Biotech Headlines

No Headlines